Wang Q, Li K, He C, et al. - This randomized controlled trial was undertaken to determine if in Budd-Chiari syndrome, routine, non-selective stenting in angioplasty could improve patency and treatment effectiveness with adequate safety. Eligible candidates were individuals, 18 to 75 years old with Budd-Chiari syndrome with a membranous obstruction or short-length stenosis (≤ 4 cm) and a Child-Pugh score of less than 13. Data revealed that the HR for restenosis was 0.04 in favor of routine stenting, with an absolute risk reduction of 35.6%. In patients with Budd-Chiari syndrome with short-length stenosis, routine stenting with angioplasty is better than angioplasty alone to prevent restenosis and is safe to use as part of first-line invasive treatment. There has been no stent fracture or migration. In similar settings and other regions where different features of Budd-Chiari syndrome are more prevalent, further validation is required.